BioSpace News Archive

ALERCELL, INC. announced that it has introduced a molecular Leukemia diagnostic platform.

Assertio Holdings, Inc., a specialty pharmaceutical company, announced that it is providing educational grant funding for the Lennox-Gastaut Syndrome Foundation’s new About LGS Treatments Kits for families coping with LGS.

BlueWind Medical, Ltd., the developer of transformative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), today announced that efficacy results of the OASIS pivotal clinical study will be presented in a late breaking session at the American Urological Association (AUA) 2023 Annual Meeting, being held in Chicago April 27th- May 1st.

SenesTech, Inc., the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, recently concluded participation at PEAK 2023, the largest trade show in the United States focused on poultry.

Lexaria Bioscience Corp. announces it has awarded the contract for clinical research organization (“CRO”) services for its expected upcoming Food and Drug Administration (“FDA”)-registered, U.S. Phase 1b Investigational New Drug (“IND”) hypertension study HYPER-H23-1 with its patented DehydraTECH-powered cannabidiol (“DehydraTECH-CBD”) to California-based InClin, Inc.

DifGen Pharmaceuticals LLC (“DifGen”) announced today that it has acquired Aveva Drug Delivery Services Inc. (“Aveva”) a fully integrated developer and manufacturer of Transdermal Delivery Systems (TDS) and Oral Dissolvable Films (ODF).

Today the Consumer Health North America division of Bayer announced a new strategic collaboration with two of New Jersey’s leading polytechnic universities – New Jersey Institute of Technology (NJIT) and Stevens Institute of Technology (Stevens).

MDimune Inc., a Korean biotech company developing BioDrone™ platform technology, has won the Bronze Award at the 2023 Edison Awards.

C2N Diagnostics, a leader in advanced brain health diagnostics, which has had a recent series of robust research and funding developments, announces two additions to its executive leadership team.

Tarsier Pharma Ltd. announced that its first-in-class immunomodulator TRS has been granted an International Nonproprietary Name of ‘Dazdotuftide”’ and has been placed on the INN Recommended List by the World Health Organization.